Interference in clinical chemistry assays by the hemoglobin-based oxygen carrier, Hemospan®

被引：10

作者：

Cameron, Scott J. ^{[1
]}

Gerhardt, Gregory ^{[1
]}

Engelstad, Michael ^{[1
]}

Young, Mark A. ^{[2
]}

Norris, Edward J. ^{[1
]}

Sokoll, Lori J. ^{[1
]}

机构：

[1] Johns Hopkins Med Inst, Dept Pathol, Div Clin Chem, Baltimore, MD 21287 USA

[2] Sangart Inc, San Diego, CA 92121 USA

来源：

CLINICAL BIOCHEMISTRY | 2009年 / 42卷 / 03期

关键词：

Hemospan; Hemoglobin based oxygen carriers (HBOC); Transfusion; Interference; Blood; Chemistry; BLOOD SUBSTITUTE; HBOC-201; MP4;

D O I：

10.1016/j.clinbiochem.2008.10.023

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Objective: To evaluate interference by the hemoglobin-based oxygen carrier Hemospan (R) on clinical laboratory assays. Design and methods: Interfering Hemospan concentrations were determined for general chemistry and cardiac marker analytes in pooled scrum and the corresponding hemolysis index was calculated. Results: Hemospan did not interfere with 20 of 35 analyzes. Hemospan produced a negative interference in serum creatinine, amylase, alkaline phosphatase, uric acid, and GGT assays and a positive interference in serum phosphate, LDH, iron, triglycerides, total protein, AST, cholesterol, magnesium, and albumin assays, and appeared to positively bias the serum cardiac troponin I (cTnI) assay only when cTnI is present in the sample. Conclusions: We present a report of assays affected by Hemospan and the threshold concentrations for interference. This study highlights the importance of interference studies in understanding the effects of hemoglobin-based oxygen carriers on results reported by the clinical laboratory. (C) 2008 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

引用

页码：221 / 224

页数：4

共 19 条

[1]

Ali AA, 2001, ANESTH ANALG, V92, P863

[2]

Björkholm M, 2005, HAEMATOLOGICA, V90, P505

[3] Effects of extreme hemodilution with hemoglobin- based O2 carriers on microvascular pressure [J].

Cabrales, P ;

Tsai, AG ;

Winslow, RM ;

Intaglietta, M .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2005, 288 (05) :H2146-H2153

[4]

Callas DD, 1997, CLIN CHEM, V43, P1744

[5]

Chance JJ, 2000, CLIN CHEM, V46, P1331

[6] Hemoglobin solutions [J].

Creteur, J ;

Vincent, JL .

CRITICAL CARE MEDICINE, 2003, 31 (12) :S698-S707

[7]

DEPALMA J, 1994, J INT FED CLIN CHEM, V6, P131

[8]

Ma ZM, 1997, CLIN CHEM, V43, P1732

[9] Hitachi Hemolytic Index correlates with HBOC-201 concentrations: Impact on suppression of analyte results [J].

Moon-Massat, Paula F. ;

Tierney, James P. ;

Hock, Karl G. ;

Scott, Mitchell G. .

CLINICAL BIOCHEMISTRY, 2008, 41 (06) :432-435

[10] Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death - A meta-analysis [J].

Natanson, Charles ;

Kern, Steven J. ;

Lurie, Peter ;

Banks, Steven M. ;

Wolfe, Sidney M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (19) :2304-2312

← 1 2 →